275
Participants
Start Date
May 30, 2023
Primary Completion Date
December 9, 2024
Study Completion Date
January 28, 2025
Bemnifosbuvir
550 mg administered orally once a day (QD) for 8 weeks
Ruzasvir
180 mg administered orally once a day (QD) for 8 weeks
Atea Study Site, Adana
Atea Study Site, Mabalacat
Atea Study Site, Chisinau
Atea Study Site, Randburg
Atea Study Site, Johannesburg
Atea Study Site, Iloilo City
Atea Study Site, Seoul
Atea Study Site, Ankara
Atea Study Site, Ankara
Atea Study Site, Seoul
Atea Study Site, Ankara
Atea Study Site, Somerset West
Atea Study Site, Bloemfontein
Atea Study Site, Denizli
Atea Study Site, Bucharest
Atea Study Site, Bucharest
Atea Study Site, Baguio City
Atea Study Site, Izmir
Atea Study Site, Kayseri
Atea Study Site, Busan
Atea Study Site, Busan
Atea Study Site, Quatre Bornes
Atea Study Site, Karachi
Atea Study Site, Karachi
Atea Study Site, San Antonio
Atea Study Site, Craiova
Atea Study Site, Rajkot
Atea Study Site, Surat
Atea Study Site, Nagpur
Atea Study Site, Belagavi
Atea Study Site, Kolkata
Atea Study Site, Constanța
Atea Study Site, Manaus
Atea Study Site, Salvador
Atea Study Site, Brasília
Atea Study Site, Rio de Janeiro
Atea Study Site, Porto Alegre
Atea Study Site, Porto Alegre
Atea Study Site, Porto Velho
Atea Study Site, Boa Vista
Atea Study Site, Botucatu
Atea Study Site, Ijuí
Atea Study Site, São José do Rio Preto
Atea Study Site, São Paulo
Atea Study Site, São Paulo
Atea Study Site, Sorocaba
Atea Study Site, Vancouver
Atea Study Site, Toronto
Atea Study Site, Bucharest
Atea Study Site, Seoul
Atea Study Site, Yangsan
Lead Sponsor
Atea Pharmaceuticals, Inc.
INDUSTRY